Phase 3 Trial of Setmelanotide in Controlling Hunger in Alström and Bardet-Biedl Patients Opens
With its first enrollee, Rhythm Pharmaceuticals has begun a pivotal Phase 3 trial to assess the therapeutic benefits of setmelanotide in patients with moderate-to-severe Bardet-Biedl syndrome…